# SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

> **NCT05405166** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 531 (actual)

## Conditions studied

- Plasma Cell Myeloma Recurrent

## Interventions

- **DRUG:** Isatuximab IV
- **DRUG:** Isatuximab SC
- **DRUG:** Dexamethasone
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Montelukast
- **DRUG:** Paracetamol / Acetaminophen
- **DRUG:** Diphenhydramine
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT05405166
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-23
- **Primary completion:** 2024-11-06
- **Final completion:** 2027-03-23
- **Target enrollment:** 531 (ACTUAL)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405166, "SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05405166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*